Segment Reporting

Since January 1, 2016, the Bayer Group has comprised the five reportable segments Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro.

The following table shows the reconciliation of EBITDA before special items of the above-mentioned segments and the reconciliation to income before income taxes of the Group:

Reconciliation of Segments’ EBITDA Before Special Items to Group Income Before Income Taxes

 

 

Q2 2016

Q2 2017

 

H1 2016

H1 2017

 

 

€ million

€ million

 

€ million

€ million

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

EBITDA before special items of segments

 

3,074

3,155

 

6,486

7,183

EBITDA before special items of Corporate Functions and Consolidation

 

(20)

(99)

 

(45)

(234)

EBITDA before special items1

 

3,054

3,056

 

6,441

6,949

Depreciation, amortization and impairment losses before special items of segments

 

(811)

(697)

 

(1,604)

(1,386)

Depreciation, amortization and impairment losses before special items of Corporate Functions and Consolidation

 

(1)

(3)

 

(3)

(6)

Depreciation, amortization and impairment losses before special items

 

(812)

(700)

 

(1,607)

(1,392)

EBIT before special items of segments

 

2,263

2,458

 

4,882

5,797

EBIT before special items of Corporate Functions and Consolidation

 

(21)

(102)

 

(48)

(240)

EBIT before special items1

 

2,242

2,356

 

4,834

5,557

Special items of segments

 

(95)

(204)

 

(365)

(287)

Special items of Corporate Functions and Consolidation

 

(9)

(1)

 

(11)

(3)

Special items1

 

(104)

(205)

 

(376)

(290)

EBIT of segments

 

2,168

2,254

 

4,517

5,510

EBIT of Corporate Functions and Consolidation

 

(30)

(103)

 

(59)

(243)

EBIT1

 

2,138

2,151

 

4,458

5,267

Financial result

 

(314)

(405)

 

(629)

(754)

Income before income taxes

 

1,824

1,746

 

3,829

4,513